ARQL ArQule Inc.

-0.08  -1%
Previous Close 6.54
Open 6.54
Price To Book 8.97
Market Cap 704758603
Shares 109,095,759
Volume 965,518
Short Ratio
Av. Daily Volume 1,504,717

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b data due 1H 2019.
ARQ 092
Overgrowth Diseases
Phase 1/2 trial ongoing.
Derazantinib (ARQ 087)
intrahepatic cholangiocarcinoma (iCCA)
Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer
Phase 1b data due 1H 2019.
Miransertib - ARQ 092
Solid tumors
Phase 1 dose escalation trial to be completed in 2019 with Phase 2 dose determined. Noted March 7, 2019 that first patient experienced an 88% tumor burden reduction after the first scan.
ARQ 531
B-cell malignancies
Phase 1b data to be presented 2H 2019.
ARQ 751
Solid tumors
Phase 1/2 trial to be initiated mid-2019.
Derazantinib (BAL087) and Atezolizumab (Tecentriq)
Urothelial cancer

Latest News

  1. ArQule, Inc. (NASDAQ:ARQL) Insiders Increased Their Holdings
  2. ArQule to Report First Quarter 2019 Financial Results on May 1, 2019
  3. Do Options Traders Know Something About ArQule (ARQL) Stock We Don't?
  4. ArQule to Present at 18th Annual Needham Healthcare Conference on April 9, 2019
  5. ArQule Announces Management Team Changes
  6. Edited Transcript of ARQL earnings conference call or presentation 7-Mar-19 2:00pm GMT
  7. ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019
  8. ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019
  9. Can Arqule Stock Continue Rocketing Higher?
  10. Why Rosetta Stone, ArQule, and Fly Leasing Jumped Today
  11. Arqule Inc (ARQL) Q4 2018 Earnings Conference Call Transcript
  12. Here's Why ArQule Is Soaring Today
  13. ArQule Reports Fourth Quarter and Full Year 2018 Financial Results
  14. Is ArQule, Inc.’s (NASDAQ:ARQL) CEO Paid At A Competitive Rate?
  15. Factors of Influence in 2019, Key Indicators and Opportunity within Conagra Brands, Pieris Pharmaceuticals, ArQule, MoneyGram International, Internap, and TIM Participacoes S.A — New Research Emphasizes Economic Growth
  16. ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome
  17. ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019
  18. ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
  19. Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer
  20. Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA)